Williams Jones & Associates’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Williams Jones & Associates’s Portfolio CELGZ Stock Details CELGZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-11,500	Closed	-$19K	–	378
2015 Q3	$19K	Hold	11,500	–	–	﹤0.01%	356
2015 Q2	$24K	Hold	11,500	–	–	﹤0.01%	375
2015 Q1	$34K	Hold	11,500	–	–	﹤0.01%	372
2014 Q4	$36K	Hold	11,500	–	–	﹤0.01%	371
2014 Q3	$39K	Hold	11,500	–	–	﹤0.01%	347
2014 Q2	$30K	Sell	11,500 -11,500	-50%	-$31.8K	﹤0.01%	353
2014 Q1	$65K	Buy	23,000 +11,500	+100%	+$34.8K	﹤0.01%	355
2013 Q4	$31K	Buy	+11,500	New	+$32.3K	﹤0.01%	338

Other funds holding CELGZ

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Muhlenkamp & Co Wexford, Pennsylvania $380M AUM 43.74% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Williams Jones & Associates's CELGZ Position: Q4 2015 in Review

Williams Jones & Associates sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2015, closing a stake of 11,500 shares — an estimated $19K sold.

Williams Jones & Associates first reported a position in CELGZ in Q4 2013 and held it in 8 quarters. The position peaked at $65K in Q1 2014. 24 funds tracked by Wall St. Rank hold CELGZ as of Q4 2015.

Williams Jones & Associates reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2015 after selling out during the quarter.
Williams Jones & Associates sold 11,500 Celgene Corporation Contingent Value Rights shares in Q4 2015, an estimated $19K.
Williams Jones & Associates first reported a position in Celgene Corporation Contingent Value Rights in Q4 2013 and held it in 8 quarters.
Williams Jones & Associates's Celgene Corporation Contingent Value Rights position peaked at $65K in Q1 2014.
24 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2015.

Based on Williams Jones & Associates's 13F filing for Q4 2015, filed 16 Feb 2016.